Ertugliflozin

• Type 2 Diabetes Mellitus
• Blood Sugar Control
• Glycemic Management
• SGLT2 Inhibitor Therapy

Ertugliflozin (Steglatro) is an oral SGLT2 inhibitor that helps adults with type 2 diabetes lower their blood sugar by causing the kidneys to excrete excess glucose in the urine. It is one of several medications in this class, alongside empagliflozin and dapagliflozin, and is also available combined with sitagliptin or metformin in fixed-dose tablets that simplify polypharmacy. While ertugliflozin does not carry the same heart failure or kidney outcome labels as some of its siblings, it is an effective glucose-lowering agent that can produce modest weight loss and a small reduction in blood pressure when added to standard therapy. Many primary care patients tolerate it well as an add-on to metformin.

Mechanism of Action

The sodium-glucose co-transporter 2 sits in the proximal tubule of the kidney and is responsible for reabsorbing roughly ninety percent of the glucose filtered out of the bloodstream. Under normal conditions almost no glucose reaches the urine because this transporter recycles it back into circulation. Ertugliflozin selectively and reversibly blocks SGLT2, lowering the renal threshold for glucose so that the kidneys begin to spill measurable amounts whenever serum glucose rises above roughly 80 to 100 mg/dL. The result is a steady, insulin-independent loss of glucose in urine that translates into improved fasting and postprandial blood sugars and a typical hemoglobin A1c reduction of about 0.7 to 1.0 percentage points across most patient populations.

Because the mechanism does not depend on insulin secretion or insulin sensitivity, ertugliflozin works regardless of beta-cell reserve and stacks well with other classes. Glucosuria carries a daily caloric loss of roughly 200 to 300 kilocalories, which produces a modest weight reduction of two to three kilograms over the first six months. Osmotic diuresis pulls water along with the glucose, lowering systolic blood pressure by three to five mmHg and reducing intravascular volume. These secondary effects explain both the benefits and the warnings — improved blood pressure and weight on one side, dehydration and orthostatic symptoms on the other. Beyond glucose, SGLT2 inhibitors as a class produce intrarenal hemodynamic changes that reduce intraglomerular pressure, mediated by tubuloglomerular feedback at the macula densa. This is the mechanism credited with the kidney-protective and cardiac-protective effects seen in outcome trials of related agents. Ertugliflozin shares this physiology even though its outcome trial did not reach significance for those endpoints. Background information on SGLT2 inhibitor therapy is available from the Endocrine Society.

Clinical Use

In the modern algorithm for type 2 diabetes, the American Diabetes Association and ACP recommend metformin as initial therapy for most patients, then layering on an agent based on coexisting conditions. SGLT2 inhibitors and GLP-1 receptor agonists have moved up the algorithm because of cardiovascular and renal benefits demonstrated in outcome trials. Ertugliflozin specifically lowers A1c effectively but did not show the same cardiovascular or kidney mortality reductions as empagliflozin or dapagliflozin in its outcome trial. For that reason it is often selected when cost or formulary access favors it, when a patient has already responded well to it historically, or when used as part of the fixed-dose combinations with sitagliptin or metformin to reduce pill burden.

It is appropriate as monotherapy in patients who cannot tolerate metformin, or more commonly as add-on therapy to metformin, sulfonylureas, DPP-4 inhibitors, or insulin. Patients who would gain the most are those carrying excess weight, those with elevated blood pressure, and those who want a once-daily oral option without the hypoglycemia risk of sulfonylureas. Ertugliflozin is less appropriate when the eGFR is below 30, when the patient has recurrent genital yeast infections, or when there is a history of diabetic ketoacidosis. Patients with known atherosclerotic cardiovascular disease, established heart failure, or chronic kidney disease are generally better served by an SGLT2 inhibitor with proven outcome benefit. Comparative effectiveness data show all SGLT2 inhibitors produce broadly similar A1c reductions, with the differentiation residing in the outcome trial results. Reading our primer on understanding A1c can help frame realistic glycemic targets and our diabetes prevention guide supports broader lifestyle context.

How to Take It

Ertugliflozin is taken once daily in the morning, with or without food. Morning dosing minimizes the chance of nighttime urination during the first few weeks while the kidneys adjust to the increased urinary glucose load. Patients should be encouraged to drink adequate fluids — usually six to eight glasses of water a day — particularly during the Florida summer when sweat losses are higher. Missed doses should be taken as soon as remembered on the same day; if it is already the next day, the missed dose is skipped without doubling up. Tablets are stored at room temperature, away from moisture. During the first week patients commonly notice increased urination and thirst; these usually settle within two weeks as a new fluid balance is established. Genital itching or discharge, especially in women, can appear early and should prompt evaluation rather than self-treatment. Patients should be instructed to hold the medication for several days before any planned major surgery or during acute illnesses with reduced oral intake to reduce DKA risk. Daily weight monitoring at home for the first few weeks helps detect problematic dehydration.

Monitoring and Follow-Up

A baseline metabolic panel including creatinine and eGFR, hemoglobin A1c, and a urinalysis are obtained before starting. Renal function is rechecked within three months and then at least annually, more often if the eGFR is between 30 and 45 or the patient is on diuretics or ACE inhibitors. Volume status and orthostatic symptoms should be reviewed at every visit, particularly in older adults. Hemoglobin A1c is checked every three to six months with a goal individualized to the patient — typically below 7 percent for most adults but more relaxed in frail older adults. Patients on insulin or sulfonylureas should monitor home glucose during the first month because doses of those agents may need reduction to avoid hypoglycemia. Red numbers that warrant prompt attention include eGFR drops of more than 30 percent from baseline, new ketones in urine, persistent symptoms of dehydration, or systolic blood pressure trending below 100 mmHg in a previously normotensive patient. Annual lipid panels are reasonable as part of broader cardiovascular risk monitoring. Foot exams every visit are particularly important given the historical signal about lower limb amputation with this class. Background on diabetes management from NIDDK is helpful patient reading.

Special Populations

Ertugliflozin should not be initiated when the eGFR is below 30 mL/min/1.73 m² and is contraindicated in patients on dialysis. No dose adjustment is needed for hepatic impairment, although severe hepatic disease has limited data and warrants caution. The medication is not recommended in the second or third trimester of pregnancy because animal data suggest adverse renal effects on the developing fetus, and breastfeeding is not advised. It is not approved in pediatric patients. Older adults are at increased risk for volume depletion, urinary tract infections, and acute kidney injury and may benefit from starting at 5 mg with closer follow-up. Patients with prior amputation, peripheral vascular disease, or active foot ulcers warrant extra caution because of class-level signals about lower limb amputation. Anyone with a history of recurrent genital mycotic infections or chronic urinary symptoms should be counseled about increased infection risk before starting. Patients on loop diuretics need particularly close attention because the additive diuretic effect can precipitate symptomatic hypotension and acute kidney injury, especially during illness or hot weather.

When to Contact Your Doctor

Call promptly for nausea, vomiting, abdominal pain, fatigue, or rapid breathing — these may signal diabetic ketoacidosis even when blood sugar is near normal. Severe perineal pain, swelling, redness, or fever can indicate Fournier's gangrene, a rare but life-threatening infection requiring emergency care. Decreased urine output, leg swelling, or new dizziness on standing may reflect kidney injury or volume depletion. Persistent genital itching, discharge, or burning with urination warrants evaluation rather than home remedies. Lightheadedness with low blood sugar after combining therapy with insulin or sulfonylureas should prompt a dose review. Any leg or foot wound that is not healing deserves the same week assessment. Persistent thirst, blurred vision, or weight loss beyond expectations may indicate inadequate glycemic control or an emerging problem.

For a personalized review of how ertugliflozin or another diabetes medication fits your treatment plan, contact us or schedule a visit with our St. Petersburg internal medicine team to discuss the right approach for your individual goals.